ENTX

Entera Bio

ENTX

Attention (50-day avg)0%

Attention rank (50-day avg)#3,161

Bullish sentiment (50-day avg)89%

Price to earnings ratio-10.7

Market capitalization465.8M

Earnings per share-0.35

Dividend yield (TTM)—

Revenue (annual)42K

Net income (annual)-11.4M

Social

What share of all stock conversation is about ENTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jul 28

$ENTX held up well and could potentially run some more, but will likely go down eventually due to dilution.
The company is now funded through 2030, which encompasses all the phase catalysts.
$ENTX is due for a bounce over $3.10.

Generated by AI

Sentiment

Of the messages about ENTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +7.69	85.12% -14.88
Bearish	—	—	0% -7.69	14.88% +14.88

Bullish· Jul 27

$ENTX has the potential for a significant price increase, similar to $DRUG last year, which rose 30x after a private placement.
The stock's institutional ownership is low, with only 16% held by institutions, indicating a potential for a strong institutional buy-in and a rise in price.
$ENTX has a clear path higher after retesting its current high of $4.20, and its strong bottom play makes it a good candidate for a significant price increase.

Bearish· Jul 27

The company's Israeli origin is seen as a red flag, with one user calling it a "scam company" and another stating "get the fuck away!"
The stock's price movement is viewed as unpredictable, with one user noting "it's like no one is holding after any halts" and another stating "premarket spikes and fades".
The company's financial situation is perceived as weak, with one user predicting a 20% drop in value by the next day's end of day, and another stating "they have no money and are being diluted".

Generated by AI

Topics

Of the messages about ENTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	37.5%	41.18%	60%
Analysts	100%	62.5%	58.82%	15.65%
Technical Analysis	0%	0%	0%	24.35%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Announcements· Jun 22

Entera Bio receives positive FDA feedback on 12-month registrational Phase 3 study for EB613, the first oral anabolic tablet in development for postmenopausal women with osteoporosis.
The FDA accepted a single, 750-patient, placebo-controlled trial with a 12-month total endpoint to support an NDA submission via the 505(b)(2) pathway.
Entera Bio's EB613 is the only oral anabolic therapy for postmenopausal osteoporosis in development, with the FDA confirming the registrational pathway and clearing the position in July 2025.

Technical Analysis· Jun 24

ENTX has shown a strong cup and handle formation, with a potential breakout above $7.
The stock has formed a bull flag on the 5-minute chart and is expected to continue its upward momentum.
A bullish double bottom has been identified, with the stock poised to test its pivot at $6.85.

Generated by AI

Community

Of the messages about ENTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	69.57%	66.67%	27.11%
Newcomers	0%	30.43%	33.33%	72.89%

Regulars· Jul 27

$ENTX is being watched for a reclaim of $4.00, which could lead to another test of the $4.20 high.
Entera Bio has secured funding for its phase 3, which is a significant development for the company.
$ENTX is primed for upside, with the stock price potentially increasing due to its current momentum.

Newcomers· Jul 28

Newcomers are expecting a bounce for $ENTX, with some anticipating a price increase to $3 or higher.
Despite dilution concerns, some $ENTX investors believe the stock can still run and may even hold for a bit.
The funding through 2030, encompassing phase catalysts, is seen as a positive development for Entera Bio Ltd. ($ENTX).

Generated by AI

News

Guggenheim Initiates Entera Bio at Buy With $11 Price Target

Entera Bio (ENTX) has an average rating of buy and mean price target of $9.75, according to analysts

5d agoYahoo Finance

Guggenheim initiates Entera Bio stock with buy rating on oral peptide platform

5d agoInvesting.com

Entera Bio Receives New Overweight Rating From Cantor Fitzgerald (NASDAQ: ENTX) - Entera Bio (NASDAQ:ENTX

WSW, NY, September 23rd, 2026, FinanceWireEntera Bio Ltd. (NASDAQ:ENTX) has been initiated with coverage by Cantor Fitzgerald, in a report titled “No More Needles! An Oral PTH For Osteoporosis”, which assigned the

6d agoBenzinga

Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX)

11d agoBenzinga

Entera Bio appoints new chief medical officer

Tipranks Press Release.

1mo agoThe Globe and Mail

Entera Bio appoints Riccardo Camisasca as chief medical officer

1mo agoInvesting.com

Also Discussed

Investors talking about ENTX also mention

#	Name	Attention
1	WHLM - Wilhelmina International, Inc.	——
2	EpicQuest Education Group International LimitedEEIQ	0%0
3	Wah Fu Education Group Limited Ordinary SharesWAFU	0%new
4	CLPS Inc.CLPS	0%new
5	SLGG - Super League Enterprise, Inc.	——
6	Socket Mobile Inc.SCKT	0%0
7	Vivani Medical Inc.VANI	0%new
8	Lixte Biotechnology Holdings Inc.LIXT	0%new
9	TKAT - Takung Art Co., Ltd.	——
10	ANGN - Angion Biomedica Corp.	——

Entera Bio Ltd.

Healthcare
Biotechnology

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered peptide and protein replacement therapies for serious unmet medical needs. Its work centers on converting complex therapies that are typically injected into mini-tablet formats designed for easier administration and improved patient adherence. The company’s technology platform supports oral delivery by stabilizing peptides in the gastrointestinal tract and enhancing absorption into the bloodstream. Entera Bio’s current pipeline includes programs targeting bone, endocrine, and metabolic disorders, with research spanning parathyroid hormone, GLP-1, and GLP-2-based therapies. The company also pursues collaborations and licensing opportunities to advance its oral drug delivery platform across selected therapeutic areas. Headquartered in Jerusalem, Israel, Entera Bio plays a specialized role in the biopharmaceutical market by addressing delivery challenges that limit the use of large-molecule medicines.

Website

Location

Kiryat Hadassah Minrav Building

Jerusalem, 9112002

Israel

Social

What share of all stock conversation is about ENTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jul 28

$ENTX held up well and could potentially run some more, but will likely go down eventually due to dilution.
The company is now funded through 2030, which encompasses all the phase catalysts.
$ENTX is due for a bounce over $3.10.

Generated by AI

Sentiment

Of the messages about ENTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +7.69	85.12% -14.88
Bearish	—	—	0% -7.69	14.88% +14.88

Bullish· Jul 27

$ENTX has the potential for a significant price increase, similar to $DRUG last year, which rose 30x after a private placement.
The stock's institutional ownership is low, with only 16% held by institutions, indicating a potential for a strong institutional buy-in and a rise in price.
$ENTX has a clear path higher after retesting its current high of $4.20, and its strong bottom play makes it a good candidate for a significant price increase.

Bearish· Jul 27

The company's Israeli origin is seen as a red flag, with one user calling it a "scam company" and another stating "get the fuck away!"
The stock's price movement is viewed as unpredictable, with one user noting "it's like no one is holding after any halts" and another stating "premarket spikes and fades".
The company's financial situation is perceived as weak, with one user predicting a 20% drop in value by the next day's end of day, and another stating "they have no money and are being diluted".

Generated by AI

Topics

Of the messages about ENTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	37.5%	41.18%	60%
Analysts	100%	62.5%	58.82%	15.65%
Technical Analysis	0%	0%	0%	24.35%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Announcements· Jun 22

Entera Bio receives positive FDA feedback on 12-month registrational Phase 3 study for EB613, the first oral anabolic tablet in development for postmenopausal women with osteoporosis.
The FDA accepted a single, 750-patient, placebo-controlled trial with a 12-month total endpoint to support an NDA submission via the 505(b)(2) pathway.
Entera Bio's EB613 is the only oral anabolic therapy for postmenopausal osteoporosis in development, with the FDA confirming the registrational pathway and clearing the position in July 2025.

Technical Analysis· Jun 24

ENTX has shown a strong cup and handle formation, with a potential breakout above $7.
The stock has formed a bull flag on the 5-minute chart and is expected to continue its upward momentum.
A bullish double bottom has been identified, with the stock poised to test its pivot at $6.85.

Generated by AI

Community

Of the messages about ENTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	69.57%	66.67%	27.11%
Newcomers	0%	30.43%	33.33%	72.89%

Regulars· Jul 27

$ENTX is being watched for a reclaim of $4.00, which could lead to another test of the $4.20 high.
Entera Bio has secured funding for its phase 3, which is a significant development for the company.
$ENTX is primed for upside, with the stock price potentially increasing due to its current momentum.

Newcomers· Jul 28

Newcomers are expecting a bounce for $ENTX, with some anticipating a price increase to $3 or higher.
Despite dilution concerns, some $ENTX investors believe the stock can still run and may even hold for a bit.
The funding through 2030, encompassing phase catalysts, is seen as a positive development for Entera Bio Ltd. ($ENTX).

Generated by AI

Entera Bio

Social

Jul 28

Bullish· Jul 27

Bearish· Jul 27

Announcements· Jun 22

Technical Analysis· Jun 24

Regulars· Jul 27

Newcomers· Jul 28

Guggenheim Initiates Entera Bio at Buy With $11 Price Target

Guggenheim initiates Entera Bio stock with buy rating on oral peptide platform

Entera Bio Receives New Overweight Rating From Cantor Fitzgerald (NASDAQ: ENTX) - Entera Bio (NASDAQ:ENTX

Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX)

Entera Bio appoints new chief medical officer

Entera Bio appoints Riccardo Camisasca as chief medical officer

Also Discussed

Entera Bio Ltd.

Company Information

Location

Guggenheim Initiates Entera Bio at Buy With $11 Price Target

Guggenheim initiates Entera Bio stock with buy rating on oral peptide platform

Entera Bio Receives New Overweight Rating From Cantor Fitzgerald (NASDAQ: ENTX) - Entera Bio (NASDAQ:ENTX

Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX)

Entera Bio appoints new chief medical officer

Entera Bio appoints Riccardo Camisasca as chief medical officer

Also Discussed

Social

Jul 28

Bullish· Jul 27

Bearish· Jul 27

Announcements· Jun 22

Technical Analysis· Jun 24

Regulars· Jul 27

Newcomers· Jul 28